Our Commitment to Safety Communication

Verified safety updates from ongoing ocrelizumab clinical trials and post-marketing experience

Indications vary in different countries. The local prescribing information from your country is the primary source of information on the known and potential risks associated with ocrelizumab.

As of April 2019, more than 100,000 patients with RMS and PPMS have started ocrelizumab globally, amounting to a total of more than 100,000 patient-years.1

The following ocrelizumab global safety updates are available. Click below to learn more: 

Updated Safety Analysis 

Additional Topics of Interest

Post-marketing Commitments

Indication:

Indications vary in different countries. Please contact your local Roche Affiliate for more information on ocrelizumab.

References

  1.  Roche data on file: April 2019, post-marketing experience; January 2019, clinical trials data cut-off